CTOs on the Move

Phathom Pharmaceuticals

www.phathompharma.com

 
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Phathom Pharmaceuticals raised $50M on 05/15/2019
Phathom Pharmaceuticals raised $90M on 05/15/2019

Similar Companies

CERTUS PHARMACEUTICALS

CERTUS PHARMACEUTICALS is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Salience TMS Neuro Solutions

Depression disconnects you from life. TMS Therapy from Salience TMS Neuro Solutions reconnects you. Offices in Dallas-Fort Worth and Houston.

G and W Laboratories

Carl Greenblatt founded G&W Laboratories, Inc. in 1919 upon his return from military service as a pharmacist with US forces in World War I. While establishing a reputation as an innovative specialist in suppository dosage forms, Carl guided G&W Laboratories with an uncompromising commitment to product integrity and customer service. In 1945, Carl’s son, Burton, also a registered pharmacist, returned from military service in World War II and joined the small but growing company. During the post-war years, G&W expanded its product line beyond suppositories, into creams, ointments, gels and liquids. G&W moved to a larger state-of-the-art laboratory and production facility, which now exceeds 180,000 square feet in South Plainfield, New Jersey. Continuing the high ethical standards and customer focus established by Carl and his son Burton Greenblatt, G&W is still family owned and operated. Burton’s son, Ronald, who joined the company in 1978 and now serves as Chief Executive Officer; and Ronald’s son, Aaron, who joined the company in 2009 after earning his Pharm.D. In addition to strong family ties the family hired Kurt Orlofski, who joined G&W as President and Chief Operating Officer in 2009.

Osmind

Osmind is building the digital infrastructure for the next era of mental health. Osmind EHR is the #1 software for treatment-resistant mental health practices such as those in psychiatry, ketamine, psychedelic medicine, and neuromodulation.

Aclario

Aclario is a Vienna, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.